Thomas Baer

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

Bayer Schering Pharma Ag

Years Active: 2009-2015

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8969401 - Sulfonylpyrroles (2015-03-03),

2. 8440830 - Tetrahydro-fused pyridines as histone deacetylase inhibitors (2013-05-14),

3. 8399505 - Sulfonylpyrroles (2013-03-19),

4. 8067615 - Sulphonylpyrroles (2011-11-29),

5. 8044065 - Benzothienopyridines for use as inhibitors of Eg5 kinesin (2011-10-25),

6. 7879853 - 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors (2011-02-01),

7. 7842820 - Sulfonylpyrroles (2010-11-30),

8. 7803945 - Tetrahydropyridothiophenes (2010-09-28),

9. 7745446 - Pyrazolo[1,5-c]pyrimidines (2010-06-29),

10. 7723523 - Tetrahydropyridothiophenes (2010-05-25),

11. 7718665 - Benzothienopyridines for use as inhibitors of Eg5 kinesin (2010-05-18),

12. 7714134 - Compounds and use of tetrahydropyridothiophenes (2010-05-11),

13. 7517986 - Tetrahydropyridothiophenes for use in the treatment of cancer (2009-04-14),

Title: The Innovative Journey of Inventor Thomas Baer

Introduction: Thomas Baer, a prominent inventor located in Reichenau, Germany, has made significant contributions to the field of pharmaceuticals with his extensive portfolio of 13 patents. His innovative work has focused on developing novel compounds that serve as effective inhibitors for crucial biological processes.

Latest Patents: Among Thomas Baer's latest patents are two noteworthy inventions. The first, titled "Sulfonylpyrroles - Compounds of a certain formula (I)," highlights novel effective HDAC inhibitors. These compounds are designed to target histone deacetylases, a key element in various cellular processes. The second patent, "Tetrahydro-fused pyridines as histone deacetylase inhibitors," presents compounds of formula (I), wherein ring D and ring E together form a fused ring system. This approach has led to the creation of new, effective inhibitors of histone deacetylases, further solidifying Baer's reputation as a leading innovator in this space.

Career Highlights: Throughout his career, Thomas Baer has worked with notable companies such as 4SC AG and Bayer Schering Pharma AG. His work at these organizations has allowed him to focus on the development of groundbreaking medical therapies, ultimately making significant impacts in healthcare and therapeutic interventions.

Collaborations: Baer has had the opportunity to collaborate with talented individuals, including Thomas Beckers and Thomas Maier. These partnerships have facilitated innovative brainstorming and the advancement of new ideas, further enriching Baer's contributions to the world of inventions.

Conclusion: Thomas Baer's journey as an inventor reflects his unwavering commitment to advancing medical science through innovation. His extensive patent portfolio and collaborations with industry leaders underscore the significance of his work in developing effective therapies. As the pharmaceutical landscape continues to evolve, Thomas Baer's contributions will undoubtedly remain influential in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.